A Partnership of Excellence

THE LEADER IN PREVENTION

Merck Animal Health is the trusted leader and advocate for disease prevention. From disease research and clinical studies, to the proven efficacy of Nobivac® vaccines, Merck Animal Health is always striving to help you keep pets safe.

A History of Nobivac®

Through Merck Animal Health, Nobivac® has made significant contributions to the development and innovation of vaccines – enabling essential progress for animal health over the decades.

1998

First company to develop a feline Bb
vaccine with Nobivac® Feline-Bb

2003

First to introduce Advanced Delivery
Technology (ADT) needleless vaccine
delivery to avoid accidental injection
of intranasal canine cough vaccines—
Nobivac® Intra-Trac® 3 ADT

2005

First USDA-approved canine distemper,
adenovirus (Hepatitis), parvovirus (DAP) vaccine with 3-year DOI—Nobivac® Canine 3-DAPv

2006

First USDA-approved feline rhinotracheitis,
calicivirus and panleukopenia virus (HCP) vaccine with a 3-year DOI—Nobivac® Feline 3-HCP

2008

Published first data demonstrating protection with our canine range against parvovirus 2c strain

2009

First to develop a Lyme vaccine,
Nobivac® Lyme, that induced borreliacidal
antibodies to outer surface protein C
First canine influenza (H3N8) vaccine with
Nobivac® Canine Flu H3N8

2010

First company to provide a FeLV vaccine with
a 2-year DOI with Nobivac® Feline 2-FeLV

First leptospirosis vaccine, Nobivac® Lepto4, with label claims against mortality and urinary shedding caused by serovars L. canicola, L. grippotyphosa, L. icterohaemorrhagiae and L. pomona

2011

Introduced VacciPure™ filtration
advancement to Nobivac® Lepto4

2011

Launched first bivalent canine influenza vaccine
protecting against both CIV H3N2 and CIV H3N8
with Nobivac® Canine Flu Bivalent

2016

Nobivac® Canine Flu H3N2: the first fully licensed vaccine to protect dogs against the new canine influenza virus strain H3N2.

Nobivac® Canine Flu Bivalent: the first fully licensed vaccine to protect dogs against both known strains of canine influenza virus H3N8 and H3N2.

Nobivac® Intra-Trac Oral Bb: is the first oral Bordetella vaccine proven by a real time duration of immunity study to protect dogs for 1 year against canine cough caused by Bordetella bronchiseptica.

2019


Nobivac® EDGE
introduced the first 0.5 mL lepto vaccine shown effective against disease, mortality and leptospiria as well as the first 0.5 mL combo vaccine to protect against parainfluenza.

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

The Infectious Disease Handbook

Stay on top of preventive care, and keep your business free from an outbreak, with this free handbook.

Download

Nobivac® Social Media Kits

Digital Assets

Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.

Learn More

COVID-19 NOBIVAC® RELIEF PLAN

Program Detailer

Financial support of up to $1,000 per case for vets who have cases of infectious diseases of vaccine preventable diseases in dogs and cats due to COVID-19 related delayed revaccination. Certain conditions apply.  

View Program

No items to show.

Loading…

References:

View All Nobivac References